Project Grant HT94252510167
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$926K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
The University of North Carolina at Chapel Hill will use a $777,500 Project Grant from the Defense Health Agency to support research aimed at reducing expression of TDP-43 protein in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The grant was awarded on April 15, 2023 under the Military Medical Research and Development program (CFDA 12.420).
Through April 14, 2025, UNC-Chapel Hill researchers will investigate medical solutions for ALS at the project site in Chapel...
This $2,905,936 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a 4-year pilot randomized clinical trial to assess early ventilation interventions for patients with amyotrophic lateral sclerosis (ALS). The award recipient, The Trustees of the University of Pennsylvania, will leverage its expertise as a renowned private research university and academic medical center to conduct this innovative clinical...
This $798,272 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at The Johns Hopkins University to test the use of WNT inhibitors as a therapeutic to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The grant, with a performance period from March 2025 to March 2027, will enable the university to conduct this innovative biomedical research study focused on developing new...
The federal Project Grant award of $1,103,084 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding the development of a personalized blood-based diagnostic assay for the early detection of amyotrophic lateral sclerosis (ALS). The prime awardee, Arizona State University's Division Orspa, is leading the research effort. The project will run from November 1, 2024 to October 31, 2026.
As a sub-award under this grant, Georgetown University is...
This federal Project Grant award, issued by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $963,000.00 to The Regents of the University of California, doing business as University of California, Berkeley, to conduct research on "REBALANCING C9ORF72 LOSS OF FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS". The research, which will take place over a two-year period from March 1, 2024 to February 28, 2026, aims to...
The Van Andel Research Institute was awarded a $950,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 30, 2023 to September 29, 2025 to establish the neuroprotective potential of C9ORF72 hypermethylation in repeat expansion-caused ALS. Through this award, the grantee will investigate medical solutions for the battlefield by transforming health care for service members and the...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The University of California, San Diego received a $694,650 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420).
The two-year award will support research on RNA-directed therapy for amyotrophic lateral sclerosis (ALS) linked to the C9ORF72 gene using engineered zinc finger nucleases. The Military Medical Research and Development program aims to transform military and public health through...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS).
Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a...